Devita, Hellman, and Rosenberg's Cancer

LWBK1006-15 LWW-Govindan-Review December 7, 2011 19:5

CHAPTER 15 ADVANCES IN

DIAGNOSTICS AND

INTERVENTION

SANJEEV BHALLA•CYLEN JAVIDAN-NEJAD

DIRECTIONS Each of the numbered items below is followed by lettered answers. Select the

ONE lettered answer that is BEST in each case unless instructed otherwise.

QUESTIONS

Question 15.1. Which of the following statements regarding the use of tumor markers in

colorectal cancer is TRUE?

A. Patients with KRAS mutations in codons 12 or 13 should not receive

anti-EGFR antibody therapy.

B. CEA is recommended as a screening for colorectal cancer.

C. CEA has limited utility in the surveillance of resected colorectal

cancer.

D. Microsatellite instability (MSI) predicts efficacy of adjuvant

chemotherapy in colorectal cancer.

Question 15.2. Tissue expression of CDX2 is characteristic of which malignancy?

A. Ovarian cancer

B. Lung cancer

C. Colon cancer

D. None of the above

Question 15.3. Patient with deficiency in UDP glucuronosyltransferase 1A1 (UGT1A1)

have increased risk for toxicity from which chemotherapy drug?

A. Irinotecan

B. 5-Fluorouracil

C. Capecitabine

D. B and C

Corresponding Chapters inCancer: Principles & Practice of Oncology,Ninth Edition: 64 (Vascular Access

and Specialized Techniques), 65 (Interventional Radiology), 66 (Functional Imaging), 67 (Molecular Imaging),

68 (Photodynamic Therapy), and 69 (Biomarkers).

161